The Foundation: Digitization at Scale
As digital pathology adoption grows, laboratories must manage increasing image volumes while maintaining image quality and workflow efficiency. High-throughput whole slide imaging provides the foundation for computational pathology by generating consistent digital datasets that support analysis, collaboration, and AI applications.
Leica Biosystems offers scalable scanning solutions designed to support routine pathology, translational research, and enterprise-wide digital pathology programs.
For high-volume laboratories, timely image acquisition is essential to supporting efficient computational pathology workflows. The Aperio GT Elite scanner is designed to deliver rapid, high-quality whole slide imaging at scale, helping laboratories generate the consistent digital datasets required for image management, collaboration, and AI-enabled analysis.
Published performance data indicates scan speeds of up to 103 slides per hour and as fast as 22 seconds per slide, helping laboratories accelerate image acquisition while minimizing manual intervention.
As digital pathology programs expand, laboratories need scalable workflows that can support growing slide volumes while maintaining operational efficiency. The Aperio GT 450 scanner provides a scalable digital pathology platform suitable for routine pathology, translational research, and enterprise deployments.
In a workflow study conducted at NeoGenomics, the Aperio GT 450 scanner demonstrated measurable efficiency improvements compared with the previous-generation Aperio AT2 Scanner, including:
- 64% improvement in throughput
- 94% reduction in quality control technician time
Research organizations working with fluorescence, multiplex imaging, FISH, and spatial biology workflows can extend computational pathology capabilities using the Aperio FL platform. By supporting both brightfield and fluorescence imaging, the Aperio FL platform enables researchers to generate digital datasets suitable for advanced quantitative tissue analysis and biomarker research.